Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 4,250 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 4,250 shares of the stock in a transaction on Friday, September 27th. The shares were sold at an average price of $24.27, for a total transaction of $103,147.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Benjamin Hohl also recently made the following trade(s):

• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total value of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.54, for a total value of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $26.68, for a total value of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.07, for a total transaction of $75,210.00.

Enliven Therapeutics Trading Up 1.8 %

Enliven Therapeutics stock traded up $0.46 during trading hours on Tuesday, reaching $26.00. 849,423 shares of the stock were exchanged, compared to its average volume of 257,450. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $27.67. The company has a market cap of $1.22 billion, a P/E ratio of -14.14 and a beta of 1.09. The stock has a 50 day moving average of $23.14 and a two-hundred day moving average of $21.71.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. On average, analysts expect that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. increased its stake in shares of Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after buying an additional 3,189 shares during the period. EntryPoint Capital LLC acquired a new position in Enliven Therapeutics in the 1st quarter valued at approximately $167,000. Baker BROS. Advisors LP bought a new position in shares of Enliven Therapeutics during the first quarter valued at $2,020,000. Blackstone Inc. bought a new position in shares of Enliven Therapeutics during the first quarter valued at $443,000. Finally, Janus Henderson Group PLC lifted its holdings in shares of Enliven Therapeutics by 74.8% during the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after purchasing an additional 305,397 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on ELVN shares. Robert W. Baird assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday. Finally, Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.